Gilder Gagnon Howe & CO LLC Arvinas, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$7.87 Billion
Q3 2024

A detailed history of Gilder Gagnon Howe & CO LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 194,343 shares of ARVN stock, worth $3.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

194,343

Previous 285,099 31.83%

Holding current value

$3.5 Million

Previous $7.59 Million 36.94%

% of portfolio

0.06%

Previous 0.1%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.66 - $32.73 $2.15 Million - $2.97 Million	-90,756 Reduced 31.83%	194,343 $4.79 Million
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $972,162 - $1.61 Million	-39,745 Reduced 12.24%	285,099 $7.59 Million
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $315,778 - $454,050	-8,680 Reduced 2.6%	324,844 $13.4 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $2.31 Million - $6.89 Million	162,674 Added 95.21%	333,524 $13.7 Million
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $4.41 Million - $6.33 Million	-224,383 Reduced 56.77%	170,850 $3.36 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $337,119 - $487,605	15,514 Added 4.09%	395,233 $9.81 Million
Q1 2023 May 15, 2023	SELL	$26.15 - $37.26 $2.27 Million - $3.24 Million	-86,870 Reduced 18.62%	379,719 $10.4 Million
Q4 2022 Feb 14, 2023	SELL	$32.47 - $57.24 $6.99 Million - $12.3 Million	-215,142 Reduced 31.56%	466,589 $16 Million
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $1.64 Million - $2.28 Million	-39,274 Reduced 5.45%	681,731 $30.3 Million
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $23 Million - $47.4 Million	-638,804 Reduced 46.98%	721,005 $30.3 Million
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $10.6 Million - $14.3 Million	-175,491 Reduced 11.43%	1,359,809 $91.5 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $526 - $769	8 Added 0.0%	1,535,300 $126 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $409,846 - $603,964	-5,599 Reduced 0.36%	1,535,292 $126 Million
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $2.88 Million - $4.01 Million	-47,637 Reduced 3.0%	1,540,891 $119 Million
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $9.75 Million - $15.3 Million	-167,594 Reduced 9.54%	1,588,528 $105 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $8.7 Million - $36.6 Million	430,862 Added 32.51%	1,756,122 $149 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $2.56 Million - $4.05 Million	-111,344 Reduced 7.75%	1,325,260 $31.3 Million
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $4.17 Million - $7.92 Million	-139,668 Reduced 8.86%	1,436,604 $48.2 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $52 Million - $85.9 Million	1,576,272 New	1,576,272 $63.5 Million
Q4 2018 Feb 14, 2019	SELL	$11.19 - $18.56 $85,637 - $142,039	-7,653 Closed	0 $0
Q3 2018 Oct 30, 2018	BUY	$16.05 - $16.87 $122,830 - $129,106	7,653 New	7,653 $129,000

Others Institutions Holding ARVN

# of Institutions

231

Shares Held

68.5M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $958M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account

Gilder Gagnon Howe & CO LLC Arvinas, Inc. Transaction History